These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36217354)

  • 41. Hepatic immune-mediatedadverseeffects of immune checkpoint inhibitors: analysis of real-life experience.
    da Silva JA; Falcão D; Cardoso C; Pires AL; Araújo A; Castro-Poças F
    Ann Hepatol; 2021 Dec; 26():100561. PubMed ID: 34653687
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol.
    Liu Y; Zhang J; Yin Z; Zhu X; Xue L; Cao B
    Thorac Cancer; 2020 Jul; 11(7):2023-2030. PubMed ID: 32379397
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer.
    Watanabe H; Kubo T; Ninomiya K; Kudo K; Minami D; Murakami E; Ochi N; Ninomiya T; Harada D; Yasugi M; Ichihara E; Ohashi K; Fujiwara K; Hotta K; Tabata M; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2019 Aug; 49(8):762-765. PubMed ID: 31090906
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study.
    Chan SL; Yip TC; Wong VW; Tse YK; Yuen BW; Luk HW; Lui RN; Chan HL; Mok TS; Wong GL
    Cancer Med; 2020 Oct; 9(19):7052-7061. PubMed ID: 32780516
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Imaging features of toxicities associated with immune checkpoint inhibitors.
    Gosangi B; McIntosh L; Keraliya A; Irugu DVK; Baheti A; Khandelwal A; Thomas R; Braschi-Amirfarzan M
    Eur J Radiol Open; 2022; 9():100434. PubMed ID: 35967881
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk factors for pneumonitis in patients with non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective analysis.
    Yamaguchi T; Shimizu J; Oya Y; Watanabe N; Hasegawa T; Horio Y; Inaba Y; Fujiwara Y
    Thorac Cancer; 2022 Mar; 13(5):724-731. PubMed ID: 35044093
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
    Wang C; Qiao W; Jiang Y; Zhu M; Shao J; Wang T; Liu D; Li W
    J Cell Physiol; 2020 May; 235(5):4913-4927. PubMed ID: 31693178
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Late-onset acute type 1 diabetes mellitus 7 months after discontinuation of pembrolizumab against lung cancer.
    Ichihara S; Kunishige M; Kadota N; Okano Y; Machida H; Hatakeyama N; Naruse K; Shinohara T; Takeuchi E
    Thorac Cancer; 2023 Jan; 14(1):81-84. PubMed ID: 36411591
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
    Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recovery from insulin dependence in immune checkpoint inhibitor-associated diabetes mellitus: A case report.
    Okubo M; Hataya Y; Fujimoto K; Iwakura T; Matsuoka N
    J Diabetes Investig; 2023 Jan; 14(1):147-150. PubMed ID: 36251515
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer.
    Dolladille C; Ederhy S; Sassier M; Cautela J; Thuny F; Cohen AA; Fedrizzi S; Chrétien B; Da-Silva A; Plane AF; Legallois D; Milliez PU; Lelong-Boulouard V; Alexandre J
    JAMA Oncol; 2020 Jun; 6(6):865-871. PubMed ID: 32297899
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018.
    Molina GE; Zubiri L; Cohen JV; Durbin SM; Petrillo L; Allen IM; Murciano-Goroff YR; Dougan M; Thomas MF; Faje AT; Rengarajan M; Guidon AC; Chen ST; Okin D; Medoff BD; Nasrallah M; Kohler MJ; Schoenfeld SR; Karp Leaf RS; Sise ME; Neilan TG; Zlotoff DA; Farmer JR; Mooradian MJ; Bardia A; Mai M; Sullivan RJ; Semenov YR; Villani AC; Reynolds KL
    Oncologist; 2021 Jun; 26(6):514-522. PubMed ID: 33655682
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immune Checkpoint Inhibitor-induced Fanconi Syndrome.
    Farid S; Latif H; Nilubol C; Kim C
    Cureus; 2020 Apr; 12(4):e7686. PubMed ID: 32431966
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors.
    Chennamadhavuni A; Abushahin L; Jin N; Presley CJ; Manne A
    Front Immunol; 2022; 13():779691. PubMed ID: 35558065
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors.
    Griewing LM; Schweizer C; Schubert P; Rutzner S; Eckstein M; Frey B; Haderlein M; Weissmann T; Semrau S; Gostian AO; Müller SK; Traxdorf M; Iro H; Zhou JG; Gaipl US; Fietkau R; Hecht M
    BMC Cancer; 2021 Mar; 21(1):314. PubMed ID: 33761922
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immune Checkpoint Inhibitor Associated Autoimmune Encephalitis, Rare and Novel Topic of Neuroimmunology: A Case Report and Review of the Literature.
    Gao Y; Pan J; Shen D; Peng L; Mao Z; Wang C; Meng H; Zhou Q; Chen S
    Brain Sci; 2022 Jun; 12(6):. PubMed ID: 35741658
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
    Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Occurrence of hepatitis in an elderly woman during the treatment of pembrolizumab for right advanced renal pelvis, ureteral cancer, and bladder cancer.
    Asatani S; Kanda T; Honda M; Ishii T; Yamana Y; Kaneko T; Mizutani T; Takahashi H; Kumagawa M; Sasaki R; Masuzaki R; Kanezawa S; Matsumoto N; Nirei K; Yamagami H; Moriyama M
    JGH Open; 2021 Jun; 5(6):722-724. PubMed ID: 34124393
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies.
    Chen X; Sheikh K; Nakajima E; Lin CT; Lee J; Hu C; Hales RK; Forde PM; Naidoo J; Voong KR
    Oncologist; 2021 Oct; 26(10):e1822-e1832. PubMed ID: 34251728
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pembrolizumab-induced hypothyroidism caused reversible increased serum creatinine levels: a case report.
    Matsuoka N; Tsuji K; Ichihara E; Hara T; Fukushima K; Toma K; Kitamura S; Inagaki K; Sugiyama H; Wada J
    BMC Nephrol; 2020 Mar; 21(1):113. PubMed ID: 32234009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.